CN109106948B - 一种口蹄疫抗原保护剂及其应用 - Google Patents
一种口蹄疫抗原保护剂及其应用 Download PDFInfo
- Publication number
- CN109106948B CN109106948B CN201811096573.3A CN201811096573A CN109106948B CN 109106948 B CN109106948 B CN 109106948B CN 201811096573 A CN201811096573 A CN 201811096573A CN 109106948 B CN109106948 B CN 109106948B
- Authority
- CN
- China
- Prior art keywords
- foot
- mouth disease
- protective agent
- reducing agent
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003223 protective agent Substances 0.000 title claims abstract description 80
- 239000000427 antigen Substances 0.000 title claims abstract description 58
- 108091007433 antigens Proteins 0.000 title claims abstract description 58
- 102000036639 antigens Human genes 0.000 title claims abstract description 58
- 241000710198 Foot-and-mouth disease virus Species 0.000 title claims abstract description 57
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 title claims abstract description 51
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 43
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 19
- 150000001413 amino acids Chemical class 0.000 claims abstract description 18
- 239000006184 cosolvent Substances 0.000 claims abstract description 18
- 229960005486 vaccine Drugs 0.000 claims abstract description 18
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 16
- 229930091371 Fructose Natural products 0.000 claims abstract description 14
- 239000005715 Fructose Substances 0.000 claims abstract description 14
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 14
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000008101 lactose Substances 0.000 claims abstract description 14
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000811 xylitol Substances 0.000 claims abstract description 14
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 14
- 229960002675 xylitol Drugs 0.000 claims abstract description 14
- 235000010447 xylitol Nutrition 0.000 claims abstract description 14
- 235000000346 sugar Nutrition 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims abstract description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 235000018102 proteins Nutrition 0.000 claims description 40
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 22
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 17
- 239000004475 Arginine Substances 0.000 claims description 11
- 102000004506 Blood Proteins Human genes 0.000 claims description 11
- 108010017384 Blood Proteins Proteins 0.000 claims description 11
- 239000004471 Glycine Substances 0.000 claims description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 11
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 11
- 235000018417 cysteine Nutrition 0.000 claims description 11
- 108010088751 Albumins Proteins 0.000 claims description 10
- 102000009027 Albumins Human genes 0.000 claims description 10
- 239000004202 carbamide Substances 0.000 claims description 10
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 9
- 239000007995 HEPES buffer Substances 0.000 claims description 9
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 abstract description 4
- 230000015556 catabolic process Effects 0.000 abstract description 3
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000032683 aging Effects 0.000 description 21
- 230000001681 protective effect Effects 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 239000007791 liquid phase Substances 0.000 description 5
- 239000012452 mother liquor Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical group SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 238000010587 phase diagram Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 101710150350 Albumin-2 Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000004227 thermal cracking Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Description
厂家 | 纯度 | |
HEPES | sigma | 分析纯 |
KCl | sigma | 分析纯 |
还原性物质 | sigma | 分析纯 |
EDTA | sigma | 分析纯 |
MgCl<sub>2</sub> | sigma | 分析纯 |
NaOH | 北京化工 | 分析纯 |
TCID50 | 其他厂家1 | 本品保护剂 | 原始抗原 |
平行实验1 | 10<sup>-7.25</sup>/0.1ml | 10<sup>-7.43</sup>/0.1ml | 10<sup>-7.33</sup>/0.1ml |
平行实验2 | 10<sup>-7.25</sup>/0.1ml | 10<sup>-7.33</sup>/0.1ml | 10<sup>-7.25</sup>/0.1ml |
平行实验3 | 10<sup>-7.33</sup>/0.1ml | 10<sup>-7.49</sup>/0.1ml | 10<sup>-7.33</sup>/0.1ml |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811096573.3A CN109106948B (zh) | 2018-09-19 | 2018-09-19 | 一种口蹄疫抗原保护剂及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811096573.3A CN109106948B (zh) | 2018-09-19 | 2018-09-19 | 一种口蹄疫抗原保护剂及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109106948A CN109106948A (zh) | 2019-01-01 |
CN109106948B true CN109106948B (zh) | 2022-03-29 |
Family
ID=64859483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811096573.3A Active CN109106948B (zh) | 2018-09-19 | 2018-09-19 | 一种口蹄疫抗原保护剂及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109106948B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114904006B (zh) * | 2022-05-27 | 2023-10-17 | 中农威特生物科技股份有限公司 | 一种口蹄疫抗原热稳定性保护剂及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1413733A (zh) * | 2002-06-19 | 2003-04-30 | 中国农业科学院兰州兽医研究所 | 口蹄疫病毒抗原保存技术 |
CN104548085A (zh) * | 2014-12-09 | 2015-04-29 | 吕宏亮 | 一种口蹄疫全病毒颗粒疫苗组合物及其制备方法和应用 |
CN108504638A (zh) * | 2017-02-28 | 2018-09-07 | 中国科学院过程工程研究所 | 一种口蹄疫灭活病毒抗原纯化或储存的方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008502605A (ja) * | 2004-06-16 | 2008-01-31 | スマート ドラッグ システムズ インコーポレイティド | 徐放性ワクチン組成物 |
US20130309273A1 (en) * | 2012-05-17 | 2013-11-21 | Kimberly Hassett | Thermostable Vaccine Compositions and Methods of Preparing Same |
JP2015516143A (ja) * | 2012-04-02 | 2015-06-08 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド |
-
2018
- 2018-09-19 CN CN201811096573.3A patent/CN109106948B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1413733A (zh) * | 2002-06-19 | 2003-04-30 | 中国农业科学院兰州兽医研究所 | 口蹄疫病毒抗原保存技术 |
CN104548085A (zh) * | 2014-12-09 | 2015-04-29 | 吕宏亮 | 一种口蹄疫全病毒颗粒疫苗组合物及其制备方法和应用 |
CN108504638A (zh) * | 2017-02-28 | 2018-09-07 | 中国科学院过程工程研究所 | 一种口蹄疫灭活病毒抗原纯化或储存的方法 |
Non-Patent Citations (1)
Title |
---|
口蹄疫疫苗保存技术研究;李正丰;《中国优秀硕士学位论文全文数据库 农业科技辑》;20100615(第6期);第一章第1.5小节和第三章 * |
Also Published As
Publication number | Publication date |
---|---|
CN109106948A (zh) | 2019-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10537630B2 (en) | Virus purification | |
Sakoonwatanyoo et al. | Growth and production of the dengue virus in C6/36 cells and identification of a laminin-binding protein as a candidate serotype 3 and 4 receptor protein | |
US6884422B1 (en) | Freeze-dried hepatitis A attenuated live vaccine and its stabilizer | |
AU7107398A (en) | Method for inactivating a virus | |
ES2731337T3 (es) | Cuantificación y caracterización de alto rendimiento de virus y sus productos | |
US20080193478A1 (en) | Inactivated Poliomyelitis Vaccine Derived From Sabin Strain Of Polio Virus | |
CN109106948B (zh) | 一种口蹄疫抗原保护剂及其应用 | |
WO2012028315A1 (en) | A stabilizer for the preparation of a dry polio injectable vaccine composition | |
AU2008342194B2 (en) | Method of producing Japanese encephalitis vaccine stably storable over long time and use of the vaccine | |
DK3010537T3 (en) | PROCEDURE FOR PREVENTING AGGREGATION OF VIRUS COMPONENTS | |
Shokri et al. | Evaluation of the thermal stability of live-attenuated Rubella vaccine (Takahashi strain) formulated and lyophilized in different stabilizers | |
KR102544928B1 (ko) | 아미노산을 유효성분으로 함유하는 동물용 백신 또는 진단용 항원의 안정성 증진용 조성물 및 이의 용도 | |
Saadh et al. | Whole-organism vaccine (attenuated and killed vaccines) | |
CN116218791B (zh) | 一种基于体内外交叉的狂犬病疫苗病毒的培养方法、及应用 | |
WO2024029469A1 (ja) | 不活化SARS-CoV-2ワクチンの製造方法、及び不活化SARS-CoV-2ワクチン、並びにSARS-CoV-2又は不活化SARS-CoV-2の精製方法、及びSARS-CoV-2抗原組成物又は不活化SARS-CoV-2抗原組成物 | |
KR20210061939A (ko) | 구제역 바이러스 백신 항원의 순도 증가 방법 | |
CN104353068A (zh) | 一种利用人二倍体细胞大规模生产狂犬疫苗的方法 | |
Selvaraj et al. | Formulation, Efficacy and Immunogenicity Studies of a Liquid State Rabies Vaccine with Magnesium Chloride as Stabilizer | |
Tavkhelidze | COVID-19 and innate immunity | |
Park et al. | Effect of Formalin Inactivation on Viral Hemorrhagic Septicemia Virus (VHSV) | |
Hsue | Studies on the Multiplication of Japanese Encephalitis Virus I. Factors Influencing Plaque Formation of Japanese Encephalitis Virus | |
WO2018201154A1 (en) | Antigenic thermostable polio vaccines & related methods | |
Sanders | Development of novel inactivated poliovirus vaccines: Breaking away from convention | |
El-Bagoury et al. | Humeral response of cattle to concentrated and purified FMD vaccine using different vaccination programmes | |
El-Okour et al. | Isolation and Identification of Foot and Mouth Disease Virus from Convalescent Sheep in Jordan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220130 Address after: 215000 station 6-013, 6 / F, No. 88, modern Avenue, Suzhou Industrial Park, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou, Jiangsu (cluster registration) Applicant after: Tiankang Pharmaceutical (Suzhou) Co.,Ltd. Address before: 830000 No. 528 Changchun South Road, Urumqi high tech Industrial Development Zone, Xinjiang Uygur Autonomous Region Applicant before: TECON BIOLOGICAL Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230506 Address after: 830000 Room 201, Building 1, No. 46 Satellite Road, Phase II, Urumqi Economic Development Zone (Toutunhe District), Xinjiang Uygur Autonomous Region Patentee after: Tiankang biopharmaceutical Co.,Ltd. Address before: 215000 station 6-013, 6 / F, No. 88, modern Avenue, Suzhou Industrial Park, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou, Jiangsu (cluster registration) Patentee before: Tiankang Pharmaceutical (Suzhou) Co.,Ltd. |